Roche’s Potential Blockbuster Breast Cancer Drug Extends Survival in Phase III

Drug Industry Daily
A A
In an earlier-than-expected success for Roche’s potential blockbuster breast cancer drug, a Phase III study found trastuzumab emtansine (T-DM1) significantly extended overall patient survival when compared with the combination of GlaxoSmithKline’s Tykerb and Roche’s Xeloda.

To View This Article:

Login

Subscribe To Drug Industry Daily